137 related articles for article (PubMed ID: 21794808)
1. [The impact of therapy with TNF-blockers on health-related quality of life in rheumatoid arthritis patients. A pilot study].
Abalos Medina GM; Ruiz Villaverde G; Sánchez Cano D; Ruiz Villaverde R; Ramírez Rodrigo J; Raya Álvarez E; Villaverde Gutiérrez C
Reumatol Clin; 2011; 7(3):167-71. PubMed ID: 21794808
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response.
Kosinski M; Kujawski SC; Martin R; Wanke LA; Buatti MC; Ware JE; Perfetto EM
Am J Manag Care; 2002 Mar; 8(3):231-40. PubMed ID: 11915973
[TBL] [Abstract][Full Text] [Related]
3. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
Heiberg MS; Nordvåg BY; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
[TBL] [Abstract][Full Text] [Related]
4. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
5. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.
Kievit W; Adang EM; Fransen J; Kuper HH; van de Laar MA; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; Van Oijen PC; Van Riel PC
Ann Rheum Dis; 2008 Sep; 67(9):1229-34. PubMed ID: 18174220
[TBL] [Abstract][Full Text] [Related]
6. [Quality of life of patients with rheumatoid arthritis undergoing out-patient treatment with TNF inhibitors].
Fernández Lisón LC; Vázquez Domínguez B; Luis Fernández J; Moreno Alvarez P; Fruns Giménez I; Liso Rubio J
Farm Hosp; 2008; 32(3):178-81. PubMed ID: 18840348
[TBL] [Abstract][Full Text] [Related]
7. Hand function tests are important and sensitive tools for assessment of treatment response in patients with rheumatoid arthritis.
Eberhardt K; Sandqvist G; Geborek P
Scand J Rheumatol; 2008; 37(2):109-12. PubMed ID: 18415767
[TBL] [Abstract][Full Text] [Related]
8. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis.
De Filippis L; Caliri A; Anghelone S; Scibilia G; Lo Gullo R; Bagnato G
Panminerva Med; 2006 Jun; 48(2):129-35. PubMed ID: 16953150
[TBL] [Abstract][Full Text] [Related]
9. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
[TBL] [Abstract][Full Text] [Related]
10. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
Mancarella L; Bobbio-Pallavicini F; Ceccarelli F; Falappone PC; Ferrante A; Malesci D; Massara A; Nacci F; Secchi ME; Manganelli S; Salaffi F; Bambara ML; Bombardieri S; Cutolo M; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Grassi W; Lapadula G; Cerinic MM; Montecucco C; Trotta F; Triolo G; Valentini G; Valesini G; Ferraccioli GF;
J Rheumatol; 2007 Aug; 34(8):1670-3. PubMed ID: 17611987
[TBL] [Abstract][Full Text] [Related]
11. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
[TBL] [Abstract][Full Text] [Related]
12. May etanercept and PTH (1-34) association heal erosions in early rheumatoid arthritis? A pilot study.
Migliore A; Massafra U; Bizzi E; Argento G; Diamanti AP; Germano V; Tormenta S; Arduini F; Iannessi F; Granatas M; Laganà B
Eur Rev Med Pharmacol Sci; 2012 Mar; 16(3):363-9. PubMed ID: 22530354
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.
Chen JS; Makovey J; Lassere M; Buchbinder R; March LM
Arthritis Care Res (Hoboken); 2014 Mar; 66(3):464-72. PubMed ID: 24022870
[TBL] [Abstract][Full Text] [Related]
14. Rapid reduction in tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid arthritis after treatment with etanercept.
Lisbona MP; Maymó J; Perich J; Almirall M; Carbonell J
Ann Rheum Dis; 2010 Jun; 69(6):1117-22. PubMed ID: 20448287
[TBL] [Abstract][Full Text] [Related]
15. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
17. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
Ernestam S; Hafström I; Werner S; Carlström K; Tengstrand B
J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
[TBL] [Abstract][Full Text] [Related]
18. Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy.
Wolfe F; Michaud K
J Rheumatol; 2007 Aug; 34(8):1674-83. PubMed ID: 17611989
[TBL] [Abstract][Full Text] [Related]
19. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
Iannone F; Trotta F; Montecucco C; Giacomelli R; Galeazzi M; Matucci-Cerinic M; Ferri C; Cutolo M; Maria Bambara L; Triolo G; Ferraccioli G; Valentini G; Lapadula G;
Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
[TBL] [Abstract][Full Text] [Related]
20. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy.
Erkan D; Yazici Y; Harrison MJ; Paget SA
Arthritis Rheum; 2002 Jun; 47(3):285-90. PubMed ID: 12115159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
